3Hong-Chao Zhou De-Zhong Xu Xue-Ping Wang Jing-Xia Zhang Ying-Huang Yong-Ping Yan Yong Zhu Bo-Quan Jin Department of Epidemiology,the Fourth Military Medical University,Xi’an 710033,Shaanxi Province,ChinaDepartment of Immunology,the Fourth Military Medical University,Xi’an 710033,Shaanxi Province,China.Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes[J].World Journal of Gastroenterology,2001,7(4):583-586. 被引量：11
3Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 2003, 21(19/20): 2461-2467.
4Zhang W, Du X, Zhao G, et al. Levamisole is a potential facilitator for the activation of Thl responses of the subunit HBV vaccination. Vaccine, 2009, 27(36): 4938-4946.
5Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin 1,2rol, 2005, 34(S1): S1-3.
6Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol, 1998, 160(2): 870-876.
7Kuroda S, Fujisawa Y, Iino S, et al. Induction of protection lever of anti-preS antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (preS2+S) protein particles (a third generation vaccine). Vaccine, 1991, 9(3): 163-169.
8Dash S, Rao KV, Panda SK. Receptor for pre-S1 (21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. JMed Virol, 1992, 37(2): 116-121.
9Goldstein ST, Zhou F, Hadler SC, et d. A mathematical model to estimate global hepatitis B disease burden and vaccination impact [J]. Int J Epidemiol, 2005, 34 (6): 1329-1339.
10Kubba AK, Taylor P, Graneek B, et al. Non-responders to hepati- tis B vaccination: a review[J]. Commun Dis Public Health, 2003, 6 (2): 106-112.
